Hanjin KAL, HD Hyundai Marine Solution, and SK Biopharmaceuticals Excluded from MSCI Korea Index

Hanjin KAL, HD Hyundai Marine Solution, and SK Biopharmaceuticals have been excluded from the MSCI Korea Index constituents.

On May 12 (local time), global equity index provider MSCI announced the results of its May regular review, making these adjustments to the Korea Index constituents.

No new stocks have been added. Previously, Rainbow Robotics and others were mentioned as potential candidates for inclusion, but it is reported that they did not meet the requirements for market capitalization and free-float market capitalization. The index rebalancing will take place after the market closes on May 29.

MSCI reviews its indices every February, May, August, and November, adjusting constituent stocks based on total market capitalization and free-float market capitalization. In February, Hyundai Engineering & Construction and Samsung Epis Holdings were newly included, while Coway, Doosan Bobcat, and LG Household & Health Care were excluded.

The MSCI Index serves as a benchmark for global investors. When a stock is included in the index, global passive funds that track this index flow in. However, when a stock is excluded, capital outflows may occur.

This content was produced with the assistance of AI translation services.